Literature DB >> 8830122

Target structures for HIV-1 inactivation by methylene blue and light.

B Bachmann1, J Knüver-Hopf, B Lambrecht, H Mohr.   

Abstract

In a photodynamic virus inactivation procedure for human fresh frozen plasma the plasma is exposed to visible light in the presence of 1 microM methylene blue. This procedure is known to inactivate HIV-1 by at least 10(6.32) TCID50/ml within 10 minutes. To elucidate the mechanism of photodynamic inactivation of HIV-1 by methylene blue/light treatment, reverse transcriptase (RT), the HIV-1 associated protein p24, and viral RNA were examined. In the dark, methylene blue up to 10 microM has no inhibitory effect on recombinant RT. In the presence of light, recombinant RT inactivation was dependent on illumination time and the concentration of methylene blue. After photoinactivation of the whole virus by methylene blue/light treatment, RT activity was also almost completely inhibited. Simultaneously, it was found by Western blotting that HIV-1 p24 and gp120 are altered in size, possibly due to protein cross-linking. In addition, it was shown by polymerase chain reaction (PCR) inhibition assay that HIV-1 inactivation leads to destruction of its RNA. In summary, methylene blue/light treatment acts on HIV-1 at different target sites: the envelope and core proteins, and the inner core structures RNA and RT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8830122     DOI: 10.1002/jmv.1890470211

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  16 in total

1.  Photodynamic therapy: a new antimicrobial approach to infectious disease?

Authors:  Michael R Hamblin; Tayyaba Hasan
Journal:  Photochem Photobiol Sci       Date:  2004-02-12       Impact factor: 3.982

Review 2.  Photodynamic therapy targeted to pathogens.

Authors:  T N Demidova; M R Hamblin
Journal:  Int J Immunopathol Pharmacol       Date:  2004 Sep-Dec       Impact factor: 3.219

3.  Inactivation of bacterial pathogens following exposure to light from a 405-nanometer light-emitting diode array.

Authors:  Michelle Maclean; Scott J MacGregor; John G Anderson; Gerry Woolsey
Journal:  Appl Environ Microbiol       Date:  2009-02-06       Impact factor: 4.792

4.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

5.  Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction.

Authors:  Jerard Seghatchian; Wilhelm G Struff; Stefan Reichenberg
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

6.  Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.

Authors:  Chisu Song; Christopher Aiken
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  A comet assay of DNA damage and repair in K562 cells after photodynamic therapy using haematoporphyrin derivative, methylene blue and meso-tetrahydroxyphenylchlorin.

Authors:  F I McNair; B Marples; C M West; J V Moore
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  Photodynamic inactivation of mammalian viruses and bacteriophages.

Authors:  Liliana Costa; Maria Amparo F Faustino; Maria Graça P M S Neves; Angela Cunha; Adelaide Almeida
Journal:  Viruses       Date:  2012-06-26       Impact factor: 5.048

Review 9.  Can biowarfare agents be defeated with light?

Authors:  Fatma Vatansever; Cleber Ferraresi; Marcelo Victor Pires de Sousa; Rui Yin; Ardeshir Rineh; Sulbha K Sharma; Michael R Hamblin
Journal:  Virulence       Date:  2013-09-25       Impact factor: 5.882

10.  Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro.

Authors:  Valeria Cagno; Chiara Medaglia; Erich Cerny; Caroline Tapparel; Andreas Cerny; Thomas Cerny; Arnaud Charles-Antoine Zwygart
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.